Current treatments for advanced hepatocellular carcinoma(HCC)have limited success in improving patients’quality of life and prolonging life expectancy.The clinical need for more efficient and safe therapies has contr...Current treatments for advanced hepatocellular carcinoma(HCC)have limited success in improving patients’quality of life and prolonging life expectancy.The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies.Recently,there has been increased interest in oncolytic viruses(OVs)as a therapeutic modality for HCC.OVs undergo selective replication in cancerous tissues and kill tumor cells.Strikingly,pexastimogene devacirepvec(Pexa-Vec)was granted an orphan drug status in HCC by the U.S.Food and Drug Administration(FDA)in 2013.Meanwhile,dozens of OVs are being tested in HCC-directed clinical and preclinical trials.In this review,the pathogenesis and current therapies of HCC are outlined.Next,we summarize multiple OVs as single therapeutic agents for the treatment of HCC,which have demonstrated certain efficacy and lowtoxicity.Emerging carrier cell-,bioengineered cell mimetic-or nonbiological vehicle-mediated OV intravenous delivery systems in HCC therapy are described.In addition,we highlight the combination treatments between oncolytic virotherapy and other modalities.Finally,the clinical challenges and prospects of OV-based biotherapy are discussed,with the aim of continuing to develop a fascinating approach in HCC patients.展开更多
针对软件定义网络中控制器单点(Software Defined Network,SDN)运行隐患的问题,本文设计一种基于Ryu控制器的一主多备集群式控制器(Cluster Ryu Controller,CRC),实现自定义OVS交换机(OpenVSwitch)连接、事件上报、状态查看、流表下发...针对软件定义网络中控制器单点(Software Defined Network,SDN)运行隐患的问题,本文设计一种基于Ryu控制器的一主多备集群式控制器(Cluster Ryu Controller,CRC),实现自定义OVS交换机(OpenVSwitch)连接、事件上报、状态查看、流表下发等功能。通过Ryu+mininet工具进行仿真实验,结果表明,当CRC中某一控制器出现故障时,不会影响到CRC与整个网络的稳定运行,有效提升SDN网络的健壮性与可靠性。展开更多
基金by the National Natural Science Foundation of China(No.81700453).
文摘Current treatments for advanced hepatocellular carcinoma(HCC)have limited success in improving patients’quality of life and prolonging life expectancy.The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies.Recently,there has been increased interest in oncolytic viruses(OVs)as a therapeutic modality for HCC.OVs undergo selective replication in cancerous tissues and kill tumor cells.Strikingly,pexastimogene devacirepvec(Pexa-Vec)was granted an orphan drug status in HCC by the U.S.Food and Drug Administration(FDA)in 2013.Meanwhile,dozens of OVs are being tested in HCC-directed clinical and preclinical trials.In this review,the pathogenesis and current therapies of HCC are outlined.Next,we summarize multiple OVs as single therapeutic agents for the treatment of HCC,which have demonstrated certain efficacy and lowtoxicity.Emerging carrier cell-,bioengineered cell mimetic-or nonbiological vehicle-mediated OV intravenous delivery systems in HCC therapy are described.In addition,we highlight the combination treatments between oncolytic virotherapy and other modalities.Finally,the clinical challenges and prospects of OV-based biotherapy are discussed,with the aim of continuing to develop a fascinating approach in HCC patients.
文摘针对软件定义网络中控制器单点(Software Defined Network,SDN)运行隐患的问题,本文设计一种基于Ryu控制器的一主多备集群式控制器(Cluster Ryu Controller,CRC),实现自定义OVS交换机(OpenVSwitch)连接、事件上报、状态查看、流表下发等功能。通过Ryu+mininet工具进行仿真实验,结果表明,当CRC中某一控制器出现故障时,不会影响到CRC与整个网络的稳定运行,有效提升SDN网络的健壮性与可靠性。
